Skip to main content
. 2021 Sep 13;12:731980. doi: 10.3389/fphar.2021.731980

FIGURE 6.

FIGURE 6

Puerarin might up-regulate SUMO2 and SUMOylation via the ER/ERK pathway. (A) Western blot analysis of p-ERK and ERK levels. Following treatment with puerarin (10, 20, and 40 μM) for 1 h, H9c2 cells were analyzed by Western blotting with antibodies against p-ERK and ERK. (B) Quantification of p-ERK and ERK expression. The results were shown as mean ± SD (n = 3). *p < 0.05. (C) Link of ER pathway to ERK activation. Following treatment with puerarin-40 μM alone or in combination with Fulvestrant-1 μM and PD 98059-10 μM for 1 h, H9c2 cells were analyzed by Western blotting with antibodies against p-ERK and ERK. (D) Quantification of p-ERK and ERK expression. The results were shown as mean ± SD (n = 3). *p < 0.05. (E) Western blot analysis for the role of ER pathway in the upregulation of SUMO2 expression and SUMOylation. Following the treatment with puerarin-40 μM alone or in combination with fulvestrant-1 μM or PD 98059-10 μM for 24 h, H9c2 cells were collected and analyzed by Western blotting with antibodies against SUMO2. (F) Quantification of SUMO2 expression and SUMOylation in panel E. The data were presented as mean ± SD (n = 3). *p < 0.05.